Femtosecond-LASIK outcomes using the VisuMax®-MEL® 80 platform for hyperopia and hyperopic astigmatism refractive surgery

xlomafota13 shared this article with you from Inoreader Femtosecond-LASIK outcomes using the VisuMax<sup>®</sup>-MEL<sup>®</sup> 80 platform for hyperopia and hyperopic astigmatism refractive surgery Via Experimental and therapeutic medicine Exp Ther Med. 2021 Mar;21(3):288. doi: 10.3892/etm.2021.9719. Epub 2021 Jan 26. ABSTRACT The present study evaluated the efficacy, the safety and the predictability of the Femtosecond laser-assisted in situ keratomileusis (Femto-LASIK) procedure for hyperopia and hyperopic astigmatism. We retrospectively analyzed the postoperative 12-month evolution of 593 eyes with hyperopia and hyperopic astigmatism that underwent Femto-LASIK treatment. The procedure was predictable and effective. No eye lost 2 lines of corrected distance visual acuity (CDVA), demonstrating a safety profile of the procedure. Nine percent of the eyes gained at least one line of CDVA. The accuracy of the spherical equivalent after 12 months was 74% within ±1.0 diopter (D) of emmetropia. The refractive outcomes were stable during the follow-up period. There were no significant complications during the procedure. Femto-LASIK using the VisuMax®-MEL® 80 platform was demonstrated to be a suitable option to correct selected cases of hyperopia and hyperopic astigmatism. A longer follow-up period is required to better assess the refractive results and to detect any further regression. PMID:33603895 | PMC:PMC7851669 | DOI:10.3892/etm.2021.9719 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.